Chen Shuqin, Chen Xia and others were chatting and laughing. After they came out of the conference room of Wellington Hospital, they were immediately stopped by some people.
International pharmaceutical companies have a particularly keen sense of smell. Of course, this has a lot to do with the fact that there are insiders in the gastroenterology department of Wellington Hospital. When they learned that these drugs were particularly effective, they naturally wanted to talk about "cooperation."
These international pharmaceutical companies have thoroughly investigated the Hong Kong Pumpkin Vine Pharmaceutical Company and discovered that it is actually a shell company that was established not long ago and its only business is to act as an agent for the sale of a Chinese drug in Hong Kong.
However, a business worth millions of dollars a year is a joke in the eyes of these pharmaceutical companies, so they think they can get the patent by spending a small amount of money, so they can't wait to come to us this time.
"Hello, Ms. Chen. I'm Chris Grayling, a manager at GlaxoSmithKline. Professor Gregory and I are good friends. I was wondering if I could have the honor of inviting you all to lunch. I think we should have a lot in common."
GlaxoSmithKline? The largest pharmaceutical company in the UK.
Just when Chen Shuqin and Chen Xia were stunned, another representative from a pharmaceutical company came forward, a woman in her 40s.
"Hello, let me introduce myself. I'm Marcia, a representative of Meiguo Huiduan Pharmaceuticals. I believe we can discuss some meaningful topics together."
Huiduan? This is awesome. It was the largest pharmaceutical company in the United States in the 1980s.
At this time, a thin yellow man emerged from among these tall white people. He bowed as soon as he came up, and you could tell which country he was from without having to guess.
"Madam, sir, I am Taro Kono, a representative of Takeda Pharmaceuticals of Japan. We are close neighbors. If there is an opportunity for cooperation, I believe that the leaders of both countries will be optimistic about it."
At the beginning of the 1980s, China and Japan were in a honeymoon period, and Kono's remarks were absolutely the main theme.
These three pharmaceutical companies are the largest pharmaceutical companies in their respective countries, and some are even among the top companies in the world. They are all here, and it is obvious that they are determined to obtain several drugs in the quadruple therapy.
Chen Xia quickly stood up and said with a smile: "I think this is not the place to talk. Why don't we go to the hotel and talk together?"
Representatives from several pharmaceutical companies looked at each other warily at their competitors, but were helpless.
Everyone knows that exclusive monopoly is the easiest business to do, but when the people from Xiangjiang Pumpkin Vine Pharmaceutical Company saw them, they were surprised and then immediately calmed down, obviously wanting to take the opportunity to discuss countermeasures.
Of course, these international pharmaceutical giants are not afraid of their bids.
On the contrary, the giants are afraid that they will not bid and refuse to transfer, which will cause trouble later.
When the open approach doesn't work, you can only resort to "lateral" tactics, which means encircling and blocking them, suppressing and banning them comprehensively, or even bypassing their patents and directly counterfeiting them. Anyway, these international giants have plenty of money, and lawsuits will drag you to death.
Although this approach is simple and crude and can ultimately achieve the goal, it often results in killing one thousand enemies but losing eight hundred of your own.
After all, this is an open industry and no one company can dominate the market alone, just like in Europe, GlaxoSmithKline is not the only one that has the final say.
Others like Sanofi of France, Roche and Novartis of Switzerland are among the top ten pharmaceutical companies in the world. In terms of strength and influence, they are not weaker than GlaxoSmithKline, and may even be stronger.
It is impossible for GlaxoSmithKline to think that it can suppress Chinese pharmaceutical companies by relying on one company.
If all their hard work ends up with the other party retaliating by cooperating with other pharmaceutical companies, then all their efforts will be in vain and they will be making things difficult for others.
After all, this is a business, there is no need to fight and kill. Cooperation and win-win are the mainstream consensus in the world, not eating alone.
So the three international pharmaceutical companies that first got the news, led by Chen Shuqin, went to the hotel where she was staying to make initial contact and prepare for a good talk. Of course, it would be best if they could obtain the patent.
On the way back to the hotel, the aunt and nephew had an urgent discussion.
"Xiao Xia, do you have any idea about how you plan to cooperate?"
"Aunt, this is what I think. After all, we are just a shell company. It is not difficult to produce medicines. The difficulty lies in whether we have sales channels and a sales team, and we lack relevant talents.
Furthermore, it is quite difficult for our drugs to enter other countries. First, we need to build a factory and then apply for registration with drug regulatory agencies in various countries. The requirements of the American FDA are particularly high.
As long as they set up some obstacles, our medicines will not be able to enter. In the final analysis, our strength is still weak. Negotiating with them is completely out of our league. Their intention this time is actually to use courtesy first and then force."
Chen Shuqin nodded.
"Yes, it's just like our Caiyunzhinan Jewelry Store. Not only do we have to be careful to avoid the top ten richest people in Hong Kong, but we also have to manage our relationships with industry associations and government agencies. If we're not careful, we'll be tricked.
After all, our strength is too weak. I'm glad you have this clear understanding. So, how do you plan to negotiate with them next?"
Chen Xia said casually, "It's simple. We don't sell patents. We use a licensing model. We get what we pay for each pill. It's that simple. The more they produce, the more we earn."
And there is another benefit to doing this. We don’t have to deal with the troubles of how to build good relations with the regulatory authorities of the country where we are located, how to sell goods in major hospitals and pharmacies, how to give corresponding kickbacks to hospitals and individual doctors, and how to increase sales.
We just sit back home and collect the money. After all, drugs like omeprazole aren't high-tech drugs. They're marketed to the general public, so sales will be very high, and our profits will be astronomical."
Chen Shuqin laughed. "How strange! In mainland China, universities now teach not only medical knowledge, but also business knowledge. But you're so poor you can't even practice free trade."
Chen Chun touched Chen Xia's head and said, "It seems that when you almost drowned in the river, your brain was completely reorganized and developed after the water entered your brain. It's like you've become a different person."
When Chen Xia heard this, sweat broke out on his back.
Chen Shuqin lived in a hotel suite, which happened to have a living room outside, but it was full with more than ten people sitting there.
Marcia, a representative of Pfizer, spoke first: "Ms. Chen, on behalf of Pfizer, we would like to acquire several of your company's patents. We are willing to invest $10 million."
Chen Xia was disgruntled when he heard this. Was he being so direct? He didn't even bother to be polite. He just started with a quote. It seemed like he still looked down on Pumpkin Vine Company.
Chris Grayling, the manager of GlaxoSmithKline, was anxious and shouted:
"Ms. Chen, our offer from GlaxoSmithKline is $20 million. I hope you can consider it."
Continue read on readnovelmtl.com